transcatheter valve replacement HEART VALVE THERAPIES
Transcatheter valve technology represents a less invasive means for treating heart valve disease and is designed to allow physicians to deliver replacement valves via a catheter through the body's cardiovascular system, thus eliminating the need to open the chest.
The CoreValve™ Evolut™ R Transcatheter Aortic Valve (TAVR) system was built on the proven foundation of the CoreValve platform. It was designed specifically to meet the clinical needs of patients with severe aortic stenosis at extreme or high risk for surgical valve replacement.
The Evolut R system provides control during deployment to assist with accurate positioning with the ability to recapture and reposition the valve.* It is the only TAVR system indicated down to 5.0 mm vessel diameter†—the lowest profile for all TAV sizes in the market today–and treats an annulus range from 17‡/18-30 mm.
Deliberate design improvements to the Evolut R valve contribute to an enhanced sealing with a more conformable frame, resulting in exceptional hemodynamics.
A Less Invasive Approach to Restore Pulmonary Valve Function
With Melody® Transcatheter Pulmonary Valve (TPV) Therapy, children and adults with dysfunctional pulmonary valve conduits have a proven treatment option designed to restore pulmonary valve function and delay the need for surgical intervention. Thousands of patients from around the world have benefited from this therapy.
The Melody valve is specifically designed to treat Right Ventricular Outflow Tract (RVOT) valve dysfunction. Comprised of a bovine jugular vein (BJV) valve sutured within a platinum iridium frame, the Melody valve has natural venous valve leaflets which open and close under minimal pressure for optimal hemodynamics. Deep coaptation of the leaflets provides valve competency across a range of conduit sizes and geometries. The Melody Valve is delivered via the Ensemble® Delivery System, which utilizes balloon-in-balloon (BIB) technology for controlled valve deployment.
Data from the US IDE Study showed strong valve performance, with approximately 98 percent of patients free from conduit reoperation at two years post-implant and 92 percent of patients free from conduit reoperation at five years post-implant.
For more information, visit www.medtronic.com/melody.
Per Instructions for Use: If the bioprosthesis has been recaptured 3 times, withdraw the recaptured bioprostheses.
Evolut R 23, 26 and 29 mm valves. 34 mm valve minimum vessel indication ≥ 5.5 mm.
Measurement for TAV–in–SAV only.